DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

Information source: Gilead Sciences
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pulmonary Arterial Hypertension

Intervention: ambrisentan (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Gilead Sciences


A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.

Clinical Details

Official title: Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: Change from baseline in the six-minute walk distance evaluated after 12 weeks of therapy compared to placebo.

Secondary outcome:

Change from baseline measured after 12 weeks of treatment compared to placebo in the Borg Dyspnea Index immediately following exercise, WHO functional class and SF-36 Health Survey.

Clinical worsening of PAH.

Assessment of the safety and tolerability of the study drug.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- 18 years of age and older

- Current diagnosis of either PPH or PAH secondary to the scleroderma spectrum of

disease, systemic lupus erythematosus, anorexigen use, or HIV infection at the Screening Visit

- Right heart catheterization, completed prior to Screening Visit must meet

pre-specified hemodynamic criteria

- Female subjects of childbearing potential must have a negative serum pregnancy test

and must agree to use a reliable double barrier method of contraception until study completion and for at least four weeks following their final study visit

- Male subjects must be informed of the potential risks of testicular tubular atrophy

and infertility associated with taking this study drug and queried regarding his understanding of the potential risks as described in the Informed Consent Form Exclusion Criteria:

- PAH due to or associated with congenital heart disease, coronary artery disease, left

heart disease, interstitial lung disease, chronic obstructive pulmonary disease, veno-occlusive disease, chronic thrombotic and/or embolic disease, or sleep apnea

- Portopulmonary hypertension

- Bosentan within four weeks prior to Screening

- Phosphodiesterase type V inhibitor or chronic prostanoid therapy within four weeks

prior to Screening

- IV inotrope use within two weeks prior to Screening

- ALT or AST lab value that is greater than 1. 5 times the upper limit of normal

- Pulmonary function tests not meeting pre-specified criteria

- Contraindication to treatment with an ERA

- History of malignancies other than basal cell carcinoma of the skin or in situ

carcinoma of the cervix within the past five years

- Females who are pregnant or breastfeeding

Locations and Contacts

Additional Information

Starting date: December 2003
Last updated: April 15, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017